Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1626-1636

  Rosen, P J ^a   Mendoza, E F ^a   Landaw, E M ^a   Mondino, B ^a   Graves, M C ^a   McBride, J H ^a   Turcillo, P ^a   deKernion, J ^a   Belldegrun, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; HYDROCORTISONE; NCI 24534; PROSTATE SPECIFIC ANTIGEN; SURAMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION;

EID: 0029983725     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1626     Document Type: Article

References (58)

1. Cancer Statistics 1995. CA 45:12-13, 1995
2. Rosen PJ: Approach to management of genitourinary tract cancers, in Kelly WN (ed): Textbook of Internal Medicine (ed 3). Philadelphia, PA, Lippincott, 1992, pp 1147-1150
3. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostate cancer. N Engl J Med 321:419-424, 1989
4. Eisenberger MA, Bezerdian L, Kalash S: A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol Clin North Am 14:695-706, 1987
5. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:287-841, 1985
6. WHO Expert Committee on Trypanosomiasis: WHO Technical Report Series, No. 247, first report. Geneva, Switzerland, World Health Organization, 1962
7. WHO Expert Committee on Onchocerciasis: WHO Technical Report Series, No. 335, second report. Geneva, Switzerland, World Health Organization, 1966
8. Mitsuya H, Popovic M, Yarchoan R, et al: Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226:172-174, 1984
9. Stein CA, Saville W, Yarchoan R, et al: Suramin and function of the adrenal cortex. Ann Intern Med 140:286, 1986 (letter)
10. Rocca R, Gill C, Myers C, et al: Suramin induced acute polyneuropathy. Proc Am Soc Clin Oncol 8:71, 1989 (abstr)
11. Levine A, Gill P, Cohen J, et al: Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann Intern Med 105:32-37, 1986
12. Taylor CW, Lui R, Fanta P, et al: Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 84:489-494, 1992
13. Fruehauf JP, Myers CA, Sinha BK, et al: Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 82:1206-1209, 1990
14. Kim JH, Sherwood ER, Sutkowski DM, et al: Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J Urol 146:171-176, 1991
15. Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84:38-42, 1992
16. Fantini J, Rognoni JB, Roccabianca M, et al: Suramin inhibits cell growth and glycolytic activity and triggers differentiation in human colonic adenocarcinoma cell clone HT-29-D4. J Biol Chem 264:10282-10286, 1989
17. Myers C, LaRocca RV, Cooper MR, et al: Role of suramin in cancer biology and treatment, in Broder S (ed): Molecular Foundations of Oncology. Baltimore, MD, Williams & Wilkins, 1991, pp 413-431
18. Hosang M: Suramin binds to platelet-derived growth factor and inhibits biological activity. J Cell Biochem 29:265-273, 1985
19. Elson SD, Browne CA, Thorburn GD: Identification of epidermal growth factor-like activity in human male reproductive tissue and fluids. J Clin Endocrinol Metab 58:589-594, 1984
20. Moscatelli D, Quarto N: Transformation of NIH 3T3 cells with basic fibroblast growth factor receptor the hst/k-fgf oncogene causes down regulation of the fibroblast growth factor receptor: Reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol 109:2519-2527, 1989
21. Wilding G, Zugmeier G, Knabbe C, et al: the role of transforming growth factors A and B in human prostate cancer cell growth. Proc Am Assoc Cancer Res 29:241, 1988 (abstr)
22. Pollak M, Richard M: Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82:1349-1352, 1990
23. Basu A, Modak MJ: Observation of the suramin-mediated inhibition of cellular and viral DNA polymerases. Biochem Biophys Res Commun 128:1395-402, 1985
24. Constantopoulos G, Rees S, Cragg BG, et al: Experimental animal model for mucopolysaccharidosis: Suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. Proc Natl Acad Sci USA 77:3700-3704, 1980
25. Stein CA, LaRocca RV, McAtee N, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989
26. Myers CA, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
27. Eisenberger MA, Reyno LM, Jodrell DI, et al: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J Natl Cancer Inst 85:611-621, 1993
28. Scher HI, Jodrell DI, Iversen JM, et al: Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52:64-70, 1992
29. Jodrell DI, Reyno LM, Sridhara R, et al: Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12:166-175, 1994
30. Tjaden UR, Reeuwijk HJ, and Van Der Greef: Bioanalysis of suramin in human plasma by ion-pair high-performance liquid chromatography. J Chromatogr 525:141-149, 1990
31. Katz D, D'Argenio DZ: Implementation and evaluation of control strategies for individual dosage regimens, with application to the aminoglycoside antibiotics. J Pharmacokinet Biopharm 14:523-537, 1986
32. Landaw EM: Model-based adaptive control for cancer chemotherapy with suramin, in Anderson JG, Katzper M (eds): Proceedings of the Simulation in Health Sciences Conference, Society for Computer Simulation, San Diego. 1994, pp 93-98
33. Landaw EM, Belldegrun AS, McBride JH, et al: Significant intrapatient and interpatient variability of suramin pharmacokinetics in prostate cancer. Proc Am Assoc Cancer Res 35:242, 1994 (abstr)
34. Wittes RE: Manual of Oncologic Therapeutics, ed 1989-90. Philadelphia, PA Lippincott, 1989, pp 628-631
35. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
36. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
37. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
38. Ralston M: Derivative-free non-linear regression, in Dixon WJ (ed): BMDP Statistical Software Manual. Berkeley, CA, University of California, pp 395-423, 1990
39. O'Donnell BP, Dawson NA, Weiss RB, et al: Suramin-induced skin reactions. Arch Dermatol 128:75-79, 1992
40. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625, 1993
41. Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
42. Sella A, Kilbourn R, Amato R, et al: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683-688, 1994
43. Ahmann FR, Schwartz J, Dorr R, et al: Suramin in hormone resistant metastatic prostate cancer: significant anticancer activity but unanticipated toxicity. Proc Am Soc Clin Oncol 10:574, 1991 (abstr)
44. Iversen J, Scher H, Motzer R, et al: Suramin: Impact of individualized pharmacokinetic dosing on outcome in patients with prostatic cancer and renal cell carcinoma. Proc Am Soc Clin Oncol 10:283, 1991 (abstr)
45. Petrylak DP, Yagoda A, O'Connor J, et al: Phase II trial of suramin in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 13:249, 1994 (abstr 780)
46. Dawson N, Sartor O, Figg D, et al: Suramin response in patients with hormone refractory prostate cancer who have progressed after hydrocortisone and withdrawal of flutamide. Proc Am Soc Clin Oncol 13:247, 1994 (abstr 775)
47. Wilding G, Rago R, Hutson P, et al: Phase I trial of a six week intermittent bolus schedule of suramin. Proc Am Soc Clin Oncol 13:233, 1994 (abstr 717)
48. Scher HI, Kelly WK: Fiutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
49. Srinivas S, Small EJ: The androgen withdrawal syndrome: Experience in a large cohort of unselected prostate cancer patients. Proc Am Urol Assoc 153:448A, 1995 (abstr 878)
50. Motzer RJ, Nanus DM, O'Moore P, et al: Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52:5775-5779, 1992
51. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1979
52. Tannock I, Osoba D, Ernst S, et al: Chemotherapy with mitoxantrone and prednisone palliates patients with hormone-resistant prostate cancer. Results of a randomized Canadian trial. Proc Am Soc Clin Oncol 14:245, 1995 (abstr 653)
53. Kelly WK, Scher H, Bajorin D, et al: The contribution of hydrocortisone to the observed response proportions of suramin. Proc Am Soc Clin Oncol 13:710, 1994 (abstr 710)
54. Reyno L, Eisenberger M, Sridhara R, et al: Safety and efficacy of pharmacologically derived fixed treatment schedule of suramin in patients with stage D prostate cancer. Proc Am Soc Clin Oncol 13:236, 1994 (abstr 729)
55. Kobayashi K, Vokes E, Janich I, et al: Suramin is safe and active in prostate cancer without adaptive control: Evidence for dose response. Proc Am Soc Clin Oncol 13:140, 1994 (abstr 353)
56. Cole DJ, Ettinghaussen SE, Pass HI, et al: Post operative complications in patients receiving suramin therapy. Surgery 116:90-95, 1994
57. Kelly Wk, Scher HI, Mazumdar M, et al: Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 11:607-615, 1993
58. Mendoza E, Hoh C, Belldegrun A, et al: Positron emission tomography (PET) in the follow-up of patients with metastatic prostate cancer. Proc Am Soc Clin Oncol, 1995 (abstr)